POTASSIUM CITRATE

Post-LOE

potassium citrate

Teva

ANDAORALTABLET, EXTENDED RELEASE

Approved

Mar 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

POTASSIUM CITRATE (potassium citrate) by Teva is orally, the metabolism of absorbed citrate produces an alkaline load. Approved for renal tubular acidosis [see clinical studies ()], hypocitraturic calcium oxalate nephrolithiasis [see clinical studies ()], uric acid lithiasis with and 1 more indications. First approved in 2018.

Drug data last refreshed 20h ago

Mechanism of Action

orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase…

Worked on POTASSIUM CITRATE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

POTASSIUM CITRATE

Mechanism of Action

Indications (1)

Clinical Trials (1)